Medication interval of adalimumab for rheumatoid arthritis patients might be extended after the achievement of low disease activity-kabuki study

Authors
Category Primary study
JournalAnnals of the Rheumatic Diseases
Year 2015
This article has no abstract
Epistemonikos ID: 64239a136b7f41e26ba300e44431e014fbe424d6
First added on: Mar 23, 2022